Physician profile
John Navas
NPI 1174780381
$7,342.82
in general payments reported to CMS, 2019-2025
13 companies · $1,902 in 2025
The $1,902 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $48.33 · 2021: $1,462 · 2022: $1,600 · 2023: $1,118 · 2024: $883 · 2025: $1,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Travel and Lodging: $1,685 · Honoraria: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.69 |
| Travel and Lodging | $1,685.24 |
| Honoraria | $257.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,716.67 | 2021-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $2,120.31 | 2021-2025 | Altaviva, Interstim |
| Abbvie INC. | $364.56 | 2023-2025 | |
| Caldera Medical, INC | $334.63 | 2021-2024 | Desara |
| Boston Scientific Corporation | $274.33 | 2019-2025 | Axonics |
| Medtronic USA, INC. | $189.23 | 2019-2020 | |
| Astellas Pharma US INC | $180.62 | 2019-2024 | Veozah |
| Coloplast Corp | $56.08 | 2023-2024 | Altis |
| Sumitomo Pharma America, INC. | $29.42 | 2025 | Gemtesa |
| Femselect INC. | $25.00 | 2024 | Enplace |
| Teleflex LLC | $21.92 | 2024 | Solesta |
| Allergan, INC. | $15.45 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Navas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.